Differentially mutated subnetworks discovery
Abstract
Problem
We study the problem of identifying differentially mutated subnetworks of a large gene–gene interaction network, that is, subnetworks that display a significant difference in mutation frequency in two sets of cancer samples. We formally define the associated computational problem and show that the problem is NPhard.
Algorithm
We propose a novel and efficient algorithm, called DAMOKLE, to identify differentially mutated subnetworks given genomewide mutation data for two sets of cancer samples. We prove that DAMOKLE identifies subnetworks with statistically significant difference in mutation frequency when the data comes from a reasonable generative model, provided enough samples are available.
Experimental results
We test DAMOKLE on simulated and real data, showing that DAMOKLE does indeed find subnetworks with significant differences in mutation frequency and that it provides novel insights into the molecular mechanisms of the disease not revealed by standard methods.
Keywords
Network analysis Somatic mutations Differential analysisIntroduction
The analysis of molecular measurements from large collections of cancer samples has revolutionized our understanding of the processes leading to a tumour through somatic mutations, changes of the DNA appearing during the lifetime of an individual [1]. One of the most important aspects of cancer revealed by recent large cancer studies is intertumour genetic heterogeneity: each tumour presents hundredsthousands mutations and no two tumours harbour the same set of DNA mutations [2].
One of the fundamental problems in the analysis of somatic mutations is the identification of the handful of driver mutations (i.e., mutations related to the disease) of each tumour, detecting them among the thousands or tens of thousands that are present in each tumour genome [3]. Intertumour heterogeneity renders the identification of driver mutations, or of driver genes (genes containing driver mutations), extremely difficult, since only few genes are mutated in a relatively large fraction of samples while most genes are mutated in a low fraction of samples in a cancer cohort [4].
Recently, several analyses (e.g, [5, 6]) have shown that interaction networks provide useful information to discover driver genes by identifying groups of interacting genes, called pathways, in which each gene is mutated at relatively low frequency while the entire group has one or more mutations in a significantly large fraction of all samples. Several networkbased methods have been developed to identify groups of interacting genes mutated in a significant fraction of tumours of a given type and have been shown to improve the detection of driver genes compared to methods that analyze genes in isolation [5, 7, 8, 9].
 1.
pathways that are common to various cancer types;
 2.
pathways that are specific to a given cancer type.
Related work
Several methods have been designed to analyze different aspects of somatic mutations in a large cohort of cancer samples in the context of networks. Some methods analyze mutations in the context of known pathways to identify the ones significantly enriched in mutations (e.g., [13]). Other methods combine mutations and large interaction networks to identify cancer subnetworks [5, 14, 15]. Networks and somatic mutations have also been used to prioritarize mutated genes in cancer [7, 8, 16, 17, 18] and for patients stratification [6, 19]. Some of these methods have been used for the identification of common mutation patterns or subnetworks in several cancer types [5, 10], but to the best of our knowledge no method has been designed to identify mutated subnetworks with a significant difference in two cohorts of cancer samples.
Few methods studied the problem of identifying subnetworks with significant differences in two sets of cancer samples using data other than mutations. [20] studied the problem of identifying optimally discriminative subnetworks of a large interaction network using gene expression data. Mall et al. [21] developed a procedure to identify statistically significant changes in the topology of biological networks. Such methods cannot be readily applied to find subnetworks with significant difference in mutation frequency in two sets of samples. Other related work use gene expression to characterize different cancer types: [22] defined a pathwaybased score that clusters samples by cancer type, while [23] defined pathwaybased features used for classification in various settings, and several methods [24, 25, 26, 27, 28] have been designed for finding subnetworks with differential gene expression.
Our contribution
In this work we study the problem of finding subnetworks with frequency of mutation that is significantly different in two sets of samples. In particular, our contributions are fourfold. First, we propose a combinatorial formulation for the problem of finding subnetworks significantly more mutated in one set of samples than in another and prove that such problem is NPhard. Second, we propose DifferentiAlly Mutated subnetwOrKs anaLysis in cancEr (DAMOKLE), a simple and efficient algorithm for the identification of subnetworks with a significant difference of mutation in two sets of samples, and analyze DAMOKLE proving that it identifies subnetworks significantly more mutated in one of two sets of samples under reasonable assumptions for the data. Third, we test DAMOKLE on simulated data, verifying experimental that DAMOKLE correctly identifies subnetworks significantly more mutated in a set of samples when enough samples are provided in input. Fourth, we test DAMOKLE on large cancer datasets comprising two cancer types, and show that DAMOKLE identifies subnetworks significantly associated with one of the two types which cannot be identified by stateoftheart methods designed for the analysis of one set of samples.
Methods and algorithms
This section presents the problem we study, the algorithm we propose for its solution, and the analysis of our algorithm. In particular, "Computational problem" section formalizes the computational problem we consider; "Algorithm" section presents DifferentiAlly Mutated subnetwOrKs anaLysis in cancEr (DAMOKLE), our algorithm for the solution of the computational problem; "Analysis of DAMOKLE" section describes the analysis of our algorithm under a reasonable generative model for mutations; "Statistical significance of the results" section presents a formal analysis of the statistical significance of subnetworks obtained by DAMOKLE; and "Permutation testing" section describes two permutation tests to assess the significance of the results of DAMOKLE for limited sample sizes.
Computational problem
We are given measurements on mutations in m genes \(\mathcal {G}=\{1,\dots ,m\}\) on two sets \({\mathcal {C}}=\{c_1,\dots ,c_{n_C}\},{\mathcal {D}}=\{d_1,\dots ,d_{n_D}\}\) of samples. Such measurements are represented by two matrices C and D, of dimension \(m \times n_C\) and \(m \times n_D\), respectively, where \(n_C\) (resp., \(n_D\)) is the number of samples in \({\mathcal {C}}\) (resp., \({\mathcal {D}}\)). \(C(i,j)=1\) (resp., \(D(i,j)=1\)) if gene i is mutated in the jth sample of \({\mathcal {C}}\) (resp., \({\mathcal {D}}\)) and \(C(i,j)=0\) (resp., \(D(i,j)=0\)) otherwise. We are also given an (undirected) graph \(G=(V,E)\), where vertices \(V = \{1,\dots ,m \}\) are genes and \((i,j) \in E\) if gene i interacts with gene j (e.g., the corresponding proteins interact).
We are interested in identifying sets of genes S, with \(S\le k\), corresponding to connected subgraphs in G and displaying a significant difference in coverage between \({\mathcal {C}}\) and \({\mathcal {D}}\), i.e., with a high value of \(c_{S}({\mathcal {C}})c_{S}({\mathcal {D}})\). We define the differential coverage \(dc_{S}({\mathcal {C}},{\mathcal {D}})\) as \(dc_{S}({\mathcal {C}},{\mathcal {D}}) = c_{S}({\mathcal {C}})c_{S}({\mathcal {D}}).\)
In particular, we study the following computational problem.
The differentially mutated subnetworks discovery problem: given a value \(\theta\) with \(\theta \in [0,1]\), find all connected subgraphs S of G of size \(\le k\) such that \(dc_{S}({\mathcal {C}},{\mathcal {D}}) \ge \theta\).
Note that by finding sets that maximize \(dc_{S}({\mathcal {C}},{\mathcal {D}})\) we identify sets with significantly more mutations in \({\mathcal {C}}\) than in \({\mathcal {D}}\), while to identify sets with significantly more mutations in \({\mathcal {D}}\) than in \({\mathcal {C}}\) we need to find sets maximizing \(dc_{S}({\mathcal {D}},{\mathcal {C}})\). In addition, note that a subgraph S in the solution may contain genes that are not mutated in \({\mathcal {C}}\cup {\mathcal {D}}\) but that are needed for the connectivity of S.
We have the following.
Theorem 1
The differentially mutated subnetworks discovery problem is NPhard.
Proof
The proof is by reduction from the connected maximum coverage problem [14]. In the connected maximum coverage problem we are given a graph G defined on a set \(V=\{v_1,\dots ,v_n\}\) of n vertices, a family \(\mathcal {P} = \{P_1,\dots ,P_n\}\) of subsets of a universe I (i.e., \(P_i \in 2^{I}\)), with \(P_i\) being the subset of I covered by \(v_i \in V\) and value k, and we want to find the subgraph \(C^* = \{v_{i_1},\dots , v_{i_k}\}\) with k nodes of G that maximizes \(\cup _{j=1}^k P_{i_j}\).
Given an instance of the connected maximum coverage problem, we define an instance of the differentially mutated subnetworks discovery problem as follows: the set \(\mathcal {G}\) of genes corresponds to the set V of vertices of G in the connected maximum coverage problem, and the graph G is the same as in the instance of the maximum coverage instance; the set \({\mathcal {C}}\) is given by the set I and the matrix C is defined as \(C_{i,j}=1\) if \(i \in P_j\), while \({\mathcal {D}}=\emptyset\).
Note that for any subgraph S of G, the differential coverage \(dc_D({\mathcal {C}},{\mathcal {D}})= c_{S}({\mathcal {C}})  c_{S}({\mathcal {D}}) = c_{S}({\mathcal {C}})\) and \(c_{S}({\mathcal {C}}) = \cup _{g \in S} P_{g}/I\). Since I is the same for all solutions, the optimal solution of the differentially mutated subnetworks discovery instance corresponds to the optimal solution to the connected maximum coverage instance, and viceversa. \(\square\)
Algorithm
The motivation for design choices of DAMOKLE are provided by the results in the next section.
Analysis of DAMOKLE
The design and analysis of DAMOKLE are based on the following generative model for the underlying biological process.
Model
For each gene \(i \in \mathcal {G}=\{1,2,...,m\}\) there is an apriori probability \(p_i\) of observing a mutation in gene i. Let \(H\subset \mathcal {G}\) be the connected subnetwork of up to k genes that is differentially mutated in samples of \({\mathcal {C}}\) w.r.t. samples of \({\mathcal {D}}\). Mutations in our samples are taken from two related distributions. In the “control” distribution F a mutation in gene i is observed with probability \(p_i\) independent of other genes’ mutations. The second distribution \(F_H\) is analogous to the distribution F but we condition on the event \(E(H)=\)“at least one gene in H is mutated in the sample”.
For genes not in H, all mutations come from distribution F. For genes in H, in a perfect experiment with no noise we would assume that samples in \({\mathcal {C}}\) are taken from \(F_H\) and samples from \({\mathcal {D}}\) are taken from F. However, to model realistic, noisy data we assume that with some probability q the “true” signal for a sample is lost, that is the sample from \({\mathcal {C}}\) is taken from F. In particular, samples in \({\mathcal {C}}\) are taken with probability \(1q\) from \(F_H\) and with probability q from F.
Let p be the probability that H has at least one mutation in samples from the control model F, \(p= 1\prod _{j\in H} (1p_j)\approx \sum _{j\in H} p_j.\) Clearly, we are only interested in sets \(H\subset \mathcal {G}\) with \(p\ll 1\).
If we focus on individual genes, the probability gene i is mutated in a sample from \({\mathcal {D}}\) is \(p_i\), while the probability that it is mutated in a sample from \({\mathcal {C}}\) is \(\frac{(1q)p_i}{1\prod _{j\in H} (1p_j)}+qp_i.\) Such a gap may be hard to detect with a small number of samples. On the other hand, the probability of E(H) (i.e., of at least one mutation in the set H) in a sample from \({\mathcal {C}}\) is \((1q) +q(1\prod _{j\in H} (1p_j)) = 1q + qp\), while the probability of E(H) in a sample from \({\mathcal {D}}\) is \(1\prod _{j\in H} (1p_j) = p\) which is a more significant gap, when \(p \ll 1.\)
The efficiency of DAMOKLE is based on two fundamental results. First we show that it is sufficient to start the search only in edges with relatively high differential coverage.
Proposition 1
If \(dc_{S}({\mathcal {C}},{\mathcal {D}}) \ge \theta,\) then, in the above generating model, with high probability (asymptotic in \(n_C\) and \(n_D\) )there exist an edge \(e \in S\) such that \(dc_{\{e\}}({\mathcal {C}},{\mathcal {D}}) \ge (\theta \epsilon )/(k1),\) for any \(\epsilon >0.\)
Proof
The second result motivates the choice, in Algorithm 2, of adding only edges that increase the score of the current solution (and to stop if there is no such edge).
Proposition 2
If subgraph S can be partitioned as \(S= S' \cup \{j\} \cup S'',\) and \(dc_{\mathcal {S'}\cup \{j\}}({\mathcal {C}},{\mathcal {D}})< dc_{\mathcal {S'}}({\mathcal {C}},{\mathcal {D}}) p p_j,\) then with high probability (asymptotic in \(n_{{\mathcal {D}}}\) ) \(dc_{S \setminus \{j\}}({\mathcal {C}},{\mathcal {D}}) > dc_{S}({\mathcal {C}},{\mathcal {D}}).\)
Proof
We first observe that if each sample in \({\mathcal {D}}\) has no more than 1 mutation in S then \(dc_{\mathcal {S'}\cup \{j\}}({\mathcal {C}},{\mathcal {D}})< dc_{\mathcal {S'}}({\mathcal {C}},{\mathcal {D}})\) implies that \(dc_{\{j\}}({\mathcal {C}},{\mathcal {D}})<0\), and therefore, under this assumption, \(dc_{S \setminus \{j\}}({\mathcal {C}},{\mathcal {D}}) > dc_{S}({\mathcal {C}},{\mathcal {D}})\).
To remove the assumption that a sample has no more than one mutation in S, we need to correct for the fraction of samples in \({\mathcal {D}}\) with mutations both in j and \(S''\). With high probability (asymptotic in \(n_D\)) this fraction is bounded by \(pp_j +\epsilon\) for any \(\epsilon >0\). \(\square\)
Statistical significance of the results
To compute a threshold that guarantees statistical confidence of our finding, we first compute a bound on the gap in a non significant set.
Theorem 2
Proof
Let \(X_1,\dots , X_{n_C}\) be independent random variables such that \(X_i=1/n_C\) if sample \(c_i\) in \({\mathcal {C}}\) has a mutation in S, otherwise \(X_i=0\). Similarly, let \(Y_1,\dots , Y_{n_D}\) be independent random variables such that \(Y_i= 1/n_D\) if sample \(d_i\) in \({\mathcal {D}}\) has a mutation in S, otherwise \(Y_i=0\).
Clearly \(dc_{S}({\mathcal {C}},{\mathcal {D}}) = \sum _{i=1}^{n_C} X_i + \sum _{i=1}^{n_D} Y_i\), and since S is not significant \(E\left[\sum _{i=1}^{n_C} X_i +\sum _{i=1}^{n_D} Y_i\right]=0\).

FWER: if we want to find just the subnetwork with significant maximum differential coverage, to bound the FWER of our method by \(\alpha\) we use the maximum \(\epsilon\) such that \(N_{k} 2e^{2 \epsilon ^2 n_{{\mathcal {C}}}n_{{\mathcal {D}}}/(n_{{\mathcal {C}}}+n_{{\mathcal {D}}})}\le \alpha .\)

FDR: if we want to find several significant subnetworks with high differential coverage, to bound the FDR by \(\alpha\) we use the maximum \(\epsilon\) such that \({N_{k} 2e^{2 \epsilon ^2 n_{{\mathcal {C}}}n_{{\mathcal {D}}}/(n_{{\mathcal {C}}}+n_{{\mathcal {D}}})}}/n(\alpha ) \le \alpha\), where \(n(\alpha )\) is the number of sets with differential coverage \(\ge \epsilon\).
Permutation testing
While Theorem 2 shows how to obtain guarantees on the statistical significance of the results of DAMOKLE by appropriately setting \(\theta\), in practice, due to relatively small sample sizes and to inevitable looseness in the theoretical guarantees, a permutation testing approach may be more effective in estimating the statistical significance of the results of DAMOKLE and provide more power for the identification of differentially mutated subnetworks.
We consider two permutation tests to assess the association of mutations in the subnetwork with the highest differential coverage found by DAMOKLE. The first test assesses whether the observed differential coverage can be obtained under the independence of mutations in genes by considering the null distribution in which each gene is mutated in a random subset (of the same cardinality as observed in the data) of all samples, independently of all other events. The second test assesses whether, under the observed marginal distributions for mutations in sets of genes, the observed differential coverage of a subnetwork can be obtained under the independence between mutations and samples’ memberships (i.e., being a sample of \({\mathcal {C}}\) or a sample of \({\mathcal {D}}\)), by randomly permuting the samples memberships.
 1.
generate N (permuted) datasets from the null distribution;
 2.
run DAMOKLE (with the same input parameters used on real data) on each of the N permuted datasets;
 3.
let x be the number of permuted datasets in which DAMOKLE reports a solution with differential coverage \(\ge dc_{S}({\mathcal {C}},{\mathcal {D}})\): then the pvalue of S is \((x+1)/(N+1)\).
Results
We implemented DAMOKLE in Python^{1} and tested it on simulated and on cancer data. Our experiments have been conducted on a Linux machine with 16 cores and 256 GB of RAM. For all our experiments we used as interaction graph G the HINT+HI2012 network^{2}, a combination of the HINT network [30] and the HI2012 [31] set of protein–protein interactions, previously used in [5]. In all cases we considered only the subnetwork with the highest differential coverage among the ones returned by DAMOKLE. We first present the results on simulated data ("Simulated data" section) and then present the results on cancer data ("Cancer data" section).
Simulated data
We tested DAMOKLE on simulated data generated as follows. We assume there is a subnetwork S of k genes with differential coverage \(dc_{S}({\mathcal {C}},{\mathcal {D}})= c\). In our simulations we set \({\mathcal {C}}={\mathcal {D}}=n\). For each sample in \({\mathcal {D}}\), each gene g in G (including genes in S) is mutated with probability \(p_g\), independently of all other events. For samples in \({\mathcal {C}}\), we first mutated each gene g with probability \(p_g\) independently of all other events. We then considered the samples of \({\mathcal {C}}\) without mutations in S, and for each such sample we mutated, with probability c, one gene of S, chosen uniformly at random. In this way c is the expectation of the differential coverage \(dc_{S}({\mathcal {C}},{\mathcal {D}})\). For genes in \(G \setminus S\) we used mutation probabilities \(p_g\) estimated from oesophageal cancer data [32]. We considered only value of \(n \ge 100\), consistent with sample sizes in most recent cancer sequencing studies. (The latest ICGC data release^{3} from April 30\(^{th}\), 2018 has data for \(\ge 500\) samples for \(81\%\) of the primary sites).
 1.
the fraction of times that DAMOKLE reported S as the solution with the highest differential coverage, and
 2.
the fraction of genes of S that are in the solution with highest differential coverage found by DAMOKLE.
We then tested the performance of DAMOKLE as a function of the number of genes k in S. We tested the ability of DAMOKLE to identify a subnetwork S with differential coverage \(dc_{S}({\mathcal {C}},{\mathcal {D}})=0.46\) in a dataset with \(n=100\) samples in both \({\mathcal {C}}\) and \({\mathcal {D}}\), when the number k of genes in S varies as \(k=5,7,9\). The results are shown in Fig. 2b. As expected, when the number of genes in S increases, the fraction of times S is the best solution as well as the fraction of genes reported in the best solution by S decreases, and for \(k=9\) the best solution found by DAMOKLE corresponds to S only \(10\%\) of the times. However, even for \(k=9\), on average most of the genes of S are reported in the best solution by DAMOKLE. Therefore DAMOKLE can be used to identify relatively large subnetworks mutated in a significantly different number of samples even when the number of samples is relatively low.
Finally, we tested the performance of DAMOKLE as the number of samples n in each set \({\mathcal {C}},{\mathcal {D}}\) increases. In particular, we tested the ability of DAMOKLE to identify a relatively large subnetwork S of \(k=10\) genes with differential coverage \(dc_S({\mathcal {C}},{\mathcal {D}}) = 0.46\) as the number of samples n increases. We analyzed simulated datasets for \(n=100, 250, 500\). The results are shown in Fig. 2. For \(n=100\), when \(k=10\), DAMOKLE never reports S as the best solution and only a small fraction of all genes in S are reported in the solution. However, for \(n=250\), while DAMOKLE still reports S as the best solution only \(10\%\) of the times, on average \(70\%\) of the genes of S are reported in the best solution. More interestingly, already for \(n=500\), DAMOKLE always reports S as the best solution. These results show that DAMOKLE can reliably identify relatively large differentially mutated subnetworks from currently available datasets of large cancer sequencing studies.
Cancer data
We use DAMOKLE to analyze somatic mutations from The Cancer Genome Atlas. We first compared two similar cancer types and two very different cancer types to test whether DAMOKLE behaves as expected on these types. We then analyzed two pairs of cancer types where differences in alterations are unclear. In all cases we run DAMOKLE with \(\theta =0.1\) and obtained pvalues with the permutation tests described in "Permutation testing" section.
Lung cancer
We used DAMOKLE to analyze 188 samples of lung squamous cell carcinoma (LUSC) and 183 samples of lung adenocarcinoma (LUAD). We only considered single nucleotide variants (SNVs)^{4} and use \(k=5\). DAMOKLE did not report any significant subnetwork, in agreement with previous work showing that these two cancer types have known differences in gene expression [33] but are much more similar with respect to SNVs [34].
Colorectal vs ovarian cancer
We used DAMOKLE to analyze 456 samples of colorectal adenocarcinoma (COADREAD) and 496 samples of ovarian serous cystadenocarcinoma (OV) using only SNVs.^{5} For \(k=5\), DAMOKLE identifies the significant (\(p<0.01\) according to both tests in "Permutation testing" section) subnetwork APC, CTNNB1, FBXO30, SMAD4, SYNE1 with differential coverage 0.81 in COADREAD w.r.t. OV. APC, CTNNB1, and SMAD4 are members of the WNT signaling and TFG\(\beta\) signaling pathways. The WNT signaling pathway is one of the cascades that regulates stemness and development, with a role in carcinogenesis that has been described mostly for colorectal cancer [35], but altered Wnt signaling is observed in many other cancer types [36]. The TFG\(\beta\) signaling pathway is involved in several processes including cell growth and apoptosis, that is deregulated in many diseases, including COADREAD [35]. The high differential coverage of the subnetwork is in accordance with COADREAD being altered mostly by SNVs and OV being altered mostly by copy number aberrations (CNAs) [37].
Esophagusstomach cancer
Diffuse gliomas
We analyzed single nucleotide variants (SNVs) and copy number aberrations (CNAs) in 509 samples of lower grade glioma (LGG) and in 303 samples of glioblastoma multiforme (GBM).^{7} We considered nonsilent SNVs, short indels, and CNAs. We removed from the analysis genes with \(<6\) mutations in both classes. By single gene analysis we identified IDH1 with high (\(>0.5\)) differential coverage, and removed alterations in such gene for the DAMOKLE analysis. We run DAMOKLE with \(k=5\) with \({\mathcal {C}}\) being the set of GBM samples and \({\mathcal {D}}\) being the set of LGG samples. The number of mutations in \({\mathcal {C}}\) and in D is not significantly different (ttest p = 0.1). DAMOKLE identifies the significant (\(p<0.01\) for both tests in "Permutation testing" section) subnetwork \(S=\) {CDKN2A, CDK4, MDM2, MDM4, RB1} (Fig. 3c, d). All genes in S are members of the p53 pathway or of the RB pathway. The p53 pathway has a key role in cell death as well as in cell division, and the RB pathway plays a crucial role in cell cycle control. Both pathways are well known glioma cancer pathways [40]. Interestingly, [41] did not report any subnetwork with significant difference in mutations between LGG and GBM samples. CDK4, MDM2, MDM4, and RB1 do not appear among the top45 genes by differential coverage. We compared the results obtained by DAMOKLE with the results obtained by HotNet2. Of the genes in our subnetwork, only CDK4 and CDKN2A are reported in a significantly mutated subnetwork (\(p <0.05\)) obtained by HotNet2 analyzing \({\mathcal {D}}\) but not analyzing \({\mathcal {C}}\), while MDM2, MDM4, and RB1 are not reported in any significant subnetwork obtained by HotNet2.
Conclusion
In this work we study the problem of finding subnetworks of a large interaction network with significant difference in mutation frequency in two sets of cancer samples. This problem is extremely important to identify mutated mechanisms that are specific to a cancer (sub)type as well as for the identification of mechanisms related to clinical features (e.g., response to therapy). We provide a formal definition of the problem and show that the associated computational problem is NPhard. We design, analyze, implement, and test a simple and efficient algorithm, DAMOKLE, which we prove identifies significant subnetworks when enough data from a reasonable generative model for cancer mutations is provided. Our results also show that the subnetworks identified by DAMOKLE cannot be identified by methods not designed for the comparative analysis of mutations in two sets of samples. We tested DAMOKLE on simulated and real data. The results on simulated data show that DAMOKLE identifies significant subnetworks with currently available sample sizes. The results on two large cancer datasets, each comprising genomewide measurements of DNA mutations in two cancer subtypes, shows that DAMOKLE identifies subnetworks that are not found by methods not designed for the comparative analysis of mutations in two sets of samples.
While we provide a first method for the differential analysis of cohorts of cancer samples, several research directions remain. First, differences in the frequency of mutation of a subnetwork in two sets of cancer cohorts may be due to external (or hidden) variables, as for example the mutation rate of each cohort. While at the moment we ensure before running the analysis that no significant difference in mutation rate is present between the two sets, performing the analysis while correcting for possible differences in such confounding variable or in others would greatly expand the applicability of our method. Second, for some interaction networks (e.g., functional ones) that are relatively more dense than the protein–protein interaction network we consider, requiring a minimum connectivity (e.g., in the form of fraction of all possible edges) in the subnetwork may be beneficial, and the design of efficient algorithms considering such requirement is an interesting direction of research. Third, different types of mutation patterns (e.g., mutual exclusivity) among two set of samples could be explored (e.g., extending the method proposed in [42]). Fourth, the inclusion of additional types of measurements, as for example gene expression, may improve the power of our method. Fifth, the inclusion of noncoding variants in the analysis may provide additional information to be leveraged to assess the significance of subnetworks.
Footnotes
Notes
Authors' contributions
FV designed the study. FV and EU designed the algorithms. FV and MCH implemented the software and performed the computational analysis. All authors interpreted the results. All authors wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work is supported, in part, by University of Padova projects SID2017 and STARS: Algorithms for Inferential Data Mining and by NSF grant IIS1247581. The results presented in this manuscript are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
 1.Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17–37. https://doi.org/10.1016/j.cell.2013.03.002.CrossRefPubMedGoogle Scholar
 2.Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32(2):185.CrossRefGoogle Scholar
 3.Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. https://doi.org/10.1126/science.1235122.CrossRefPubMedPubMedCentralGoogle Scholar
 4.Vandin F. Computational methods for characterizing cancer mutational heterogeneity. Front Genet. 2017;8:83.CrossRefGoogle Scholar
 5.Leiserson MDM, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, Papoutsaki A, Kim Y, Niu B, McLellan M, Lawrence MS, GonzalezPerez A, Tamborero D, Cheng Y, Ryslik GA, LopezBigas N, Getz G, Ding L, Raphael BJ. Pancancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2015;47(2):106–14. https://doi.org/10.1038/ng.3168.CrossRefPubMedGoogle Scholar
 6.Hofree M, Shen JP, Carter H, Gross A, Ideker T. Networkbased stratification of tumor mutations. Nat Methods. 2013;10(11):1108–15. https://doi.org/10.1038/nmeth.2651.CrossRefPubMedPubMedCentralGoogle Scholar
 7.Shrestha R, Hodzic E, Sauerwald T, Dao P, Wang K, Yeung J, Anderson S, Vandin F, Haffari G, Collins CC, et al. HIT’nDRIVE: patientspecific multidriver gene prioritization for precision oncology. Genome Res. 2017;27(9):1573–88.CrossRefGoogle Scholar
 8.Hristov BH, Singh M. Networkbased coverage of mutational profiles reveals cancer genes. arXiv preprint arXiv:1704.08544. 2017.
 9.Cowen L, Ideker T, Raphael BJ, Sharan R. Network propagation: a universal amplifier of genetic associations. Nat Rev Genet. 2017;18(9):551.CrossRefGoogle Scholar
 10.Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–44.CrossRefGoogle Scholar
 11.Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9. https://doi.org/10.1038/nature12634.CrossRefPubMedPubMedCentralGoogle Scholar
 12.Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703.CrossRefGoogle Scholar
 13.Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. Inference of patientspecific pathway activities from multidimensional cancer genomics data using paradigm. Bioinformatics. 2010;26(12):237–45.CrossRefGoogle Scholar
 14.Vandin F, Upfal E, Raphael BJ. Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol. 2011;18(3):507–22.CrossRefGoogle Scholar
 15.Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012;22(2):398–406.CrossRefGoogle Scholar
 16.Kim YA, Cho DY, Dao P, Przytycka TM. Memcover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types. Bioinformatics. 2015;31(12):284–92.CrossRefGoogle Scholar
 17.PulidoTamayo S, Weytjens B, De Maeyer D, Marchal K. SSAME detection of cancer driver genes using mutual exclusivity by small subnetwork analysis. Sci Rep. 2016;6:36257.CrossRefGoogle Scholar
 18.Cho A, Shim JE, Kim E, Supek F, Lehner B, Lee I. MUFFINN: cancer gene discovery via network analysis of somatic mutation data. Genome Biol. 2016;17(1):129.CrossRefGoogle Scholar
 19.Le Morvan M, Zinovyev A, Vert JP. Netnorm: capturing cancerrelevant information in somatic exome mutation data with gene networks for cancer stratification and prognosis. PLoS Computat Biol. 2017;13(6):1005573.CrossRefGoogle Scholar
 20.Dao P, Wang K, Collins C, Ester M, Lapuk A, Sahinalp SC. Optimally discriminative subnetwork markers predict response to chemotherapy. Bioinformatics. 2011;27(13):205–13.CrossRefGoogle Scholar
 21.Mall R, Cerulo L, Bensmail H, Iavarone A, Ceccarelli M. Detection of statistically significant network changes in complex biological networks. BMC Syst Biol. 2017;11(1):32.CrossRefGoogle Scholar
 22.Young MR, Craft DL. Pathwayinformed classification system (PICS) for cancer analysis using gene expression data. Cancer Inform. 2016;15:40088.CrossRefGoogle Scholar
 23.Kim S, Kon M, DeLisi C. Pathwaybased classification of cancer subtypes. Biol Direct. 2012;7(1):21.CrossRefGoogle Scholar
 24.Ideker T, Ozier O, Schwikowski B, Siegel AF. Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics. 2002;18(suppl–1):233–40.CrossRefGoogle Scholar
 25.Dittrich MT, Klau GW, Rosenwald A, Dandekar T, Müller T. Identifying functional modules in protein–protein interaction networks: an integrated exact approach. Bioinformatics. 2008;24(13):223–31.CrossRefGoogle Scholar
 26.Gu J, Chen Y, Li S, Li Y. Identification of responsive gene modules by networkbased gene clustering and extending: application to inflammation and angiogenesis. BMC Syst Biol. 2010;4(1):47.CrossRefGoogle Scholar
 27.Jiao Y, Widschwendter M, Teschendorff AE. A systemslevel integrative framework for genomewide DNA methylation and gene expression data identifies differential gene expression modules under epigenetic control. Bioinformatics. 2014;30(16):2360–6.CrossRefGoogle Scholar
 28.He H, Lin D, Zhang J, Wang Yp, Deng Hw. Comparison of statistical methods for subnetwork detection in the integration of gene expression and protein interaction network. BMC Bioinform. 2017;18(1):149.CrossRefGoogle Scholar
 29.Mitzenmacher M, Upfal E. Probability and computing: randomization and probabilistic techniques in algorithms and data analysis. Cambridge: Cambridge University Press; 2017.Google Scholar
 30.Das J, Yu H. HINT: highquality protein interactomes and their applications in understanding human disease. BMC Syst Biol. 2012;6:92. https://doi.org/10.1186/17520509692.CrossRefPubMedPubMedCentralGoogle Scholar
 31.Yu H, Tardivo L, Tam S, Weiner E, Gebreab F, Fan C, Svrzikapa N, HirozaneKishikawa T, Rietman E, Yang X, Sahalie J, SalehiAshtiani K, Hao T, Cusick ME, Hill DE, Roth FP, Braun P, Vidal M. Nextgeneration sequencing to generate interactome datasets. Nat Methods. 2011;8(6):478–80. https://doi.org/10.1038/nmeth.1597.CrossRefPubMedPubMedCentralGoogle Scholar
 32.Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.CrossRefGoogle Scholar
 33.Sun F, Yang X, Jin Y, Chen L, Wang L, Shi M, Zhan C, Shi Y, Wang Q. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using the cancer genome atlas expression data. Mol Med Rep. 2017;16(1):609–16.CrossRefGoogle Scholar
 34.Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R, Lu Y, Kurie J, Gibbons DL, Mills GB, et al. Multiplatformbased molecular subtypes of nonsmallcell lung cancer. Oncogene. 2017;36(10):1384.CrossRefGoogle Scholar
 35.Network Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330.CrossRefGoogle Scholar
 36.Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461.CrossRefGoogle Scholar
 37.Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127.CrossRefGoogle Scholar
 38.Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H, Rajagopal J, Ramaswamy S, Ellisen LW. ACTL6A is coamplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis. Cancer Cell. 2017;31(1):35–49.CrossRefGoogle Scholar
 39.Lu C, Allis CD. SWI/SNF complex in cancer. Nat Genet. 2017;49(2):178–9.CrossRefGoogle Scholar
 40.Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–99.CrossRefGoogle Scholar
 41.Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–63.CrossRefGoogle Scholar
 42.Basso RS, Hochbaum DS, Vandin F. Efficient algorithms to discover alterations with complementary functional association in cancer. arXiv preprint arXiv:1803.09721. 2018.
Copyright information
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.